|
Validation of 3-factor clinical-genomic model to predict response to atezolizumab as first-line or post-platinum therapy for advanced urothelial carcinoma. |
|
|
|
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi |
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice |
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group |
|
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; Novartis |
Research Funding - AADi; Genentech/Roche; Revolution Medicines |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
No Relationships to Disclose |